The interview will examine the accelerated FDA approval of VOYXACT (sibeprenlimab-szsi) for the reduction of proteinuria in adults with primary IgA nephropathy at risk of disease progression. Discussion will focus on the Phase 3 VISIONARY interim findings, the clinical relevance of the 51% placebo-adjusted proteinuria reduction, APRIL blockade as a first-in-class mechanism, safety considerations, and expectations for confirmatory eGFR outcomes in 2026 as Otsuka seeks full approval.